IQVIA (NYSE:IQV) Issues Quarterly Earnings Results, Misses Expectations By $0.21 EPS

IQVIA (NYSE:IQV) released its quarterly earnings results on Thursday. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21), Zacks reports. IQVIA had a return on equity of 28.17% and a net margin of 9.17%. IQVIA updated its FY 2025 guidance to 11.700-12.100 EPS.

IQVIA Price Performance

IQV stock traded up $4.32 during midday trading on Thursday, reaching $209.76. 1,799,200 shares of the stock were exchanged, compared to its average volume of 1,427,870. The stock has a market capitalization of $38.07 billion, a PE ratio of 27.53, a P/E/G ratio of 2.15 and a beta of 1.48. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a fifty day moving average price of $200.36 and a 200 day moving average price of $219.87.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday. Robert W. Baird lowered their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Leerink Partners restated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $254.53.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.